| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 1409 |
| 1 | CYCLOPHOSPHAMIDE | 1264 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 1264 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1264 |
| 4 | DEXAMETHASONE | 1221 |
| 5 | DEXAMETHASONE 1.5 MG | 1221 |
| 6 | VENETOCLAX | 1180 |
| 7 | PREDNISONE | 870 |
| 8 | ALLOPURINOL | 868 |
| 9 | DOXORUBICIN | 835 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | RASBURICASE | 364 | 0.1471 |
| 1 | OBINUTUZUMAB | 344 | 0.0203 |
| 2 | VENETOCLAX | 1180 | 0.0188 |
| 3 | BENDAMUSTINE HYDROCHLORIDE | 148 | 0.0174 |
| 4 | CHLORAMBUCIL | 60 | 0.0153 |
| 5 | VANCOMYCIN HYDROCHLORIDE | 118 | 0.0141 |
| 6 | AZACITIDINE | 400 | 0.0133 |
| 7 | FEBUXOSTAT TABLETS 40 MG | 129 | 0.0124 |
| 8 | BENDAMUSTINE HCL | 185 | 0.0118 |
| 9 | ETOPOSIDE | 787 | 0.0107 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 2512 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 1755 |
| 2 | Alkylating Drug [EPC] | 1499 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 1402 |
| 4 | BCL-2 Inhibitor [EPC] | 1180 |
| 5 | Platinum-based Drug [EPC] | 1165 |
| 6 | Xanthine Oxidase Inhibitor [EPC] | 997 |
| 7 | Kinase Inhibitor [EPC] | 900 |
| 8 | Topoisomerase Inhibitor [EPC] | 794 |
| 9 | Proteasome Inhibitor [EPC] | 659 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD123 Interaction [EPC] | 27 | 0.0502 |
| 1 | CD38-directed Cytolytic Antibody [EPC] | 256 | 0.0437 |
| 2 | Human Immunoglobulin [EPC] | 1 | 0.0196 |
| 3 | BCL-2 Inhibitor [EPC] | 1180 | 0.0188 |
| 4 | Anthracycline Topoisomerase Inhibitor [EPC] | 28 | 0.0115 |
| 5 | CD22-directed Immunoconjugate [EPC] | 33 | 0.0110 |
| 6 | Topoisomerase Inhibitor [EPC] | 794 | 0.0103 |
| 7 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 41 | 0.0101 |
| 8 | CD33-directed Immunoconjugate [EPC] | 33 | 0.0090 |
| 9 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 12 | 0.0079 |